These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19276264)

  • 1. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
    ElBayoumi TA; Torchilin VP
    Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.
    Elbayoumi TA; Torchilin VP
    Mol Pharm; 2009; 6(1):246-54. PubMed ID: 19049322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
    Elbayoumi TA; Torchilin VP
    Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
    Lukyanov AN; Elbayoumi TA; Chakilam AR; Torchilin VP
    J Control Release; 2004 Nov; 100(1):135-44. PubMed ID: 15491817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
    Gupta B; Torchilin VP
    Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
    Elbayoumi TA; Torchilin VP
    Int J Pharm; 2008 Jun; 357(1-2):272-9. PubMed ID: 18329201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
    Elbayoumi TA; Torchilin VP
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1196-205. PubMed ID: 16763815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
    Elbayoumi TA; Pabba S; Roby A; Torchilin VP
    J Liposome Res; 2007; 17(1):1-14. PubMed ID: 17454399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
    Apte A; Koren E; Koshkaryev A; Torchilin VP
    Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo.
    Gupta B; Levchenko TS; Mongayt DA; Torchilin VP
    J Drug Target; 2005 Jul; 13(6):337-43. PubMed ID: 16278153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
    Koren E; Apte A; Jani A; Torchilin VP
    J Control Release; 2012 Jun; 160(2):264-73. PubMed ID: 22182771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
    Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
    Yalamarty SSK; Filipczak N; Pathrikar T; Cotter C; Ataide JA; Luther E; Paranjape S; Torchilin V
    Drug Deliv Transl Res; 2024 Aug; 14(8):2171-2185. PubMed ID: 38507033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
    Narayanaswamy R; Torchilin VP
    Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
    Erdogan S; Roby A; Torchilin VP
    Mol Pharm; 2006; 3(5):525-30. PubMed ID: 17009851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.